comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 04:13:19 - browse：7839

Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recording from the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit.

For more on what we cover, here’s the news on Sarepta; here’s more on Nvidia; here’s the story on Centerview; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Was Amgen transparent enough on FDA's concern on cancer drug?

WSS

Stroke deaths set to near 10 million globally by 2050

Senate panel eyes new effort on drug shortages

Heart disease and mental health: A look at cardiac psychology

Heart disease and mental health: A look at cardiac psychology

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

FDA rejects Alnylam's heart disease treatment over insufficient data

Wikipedia

comprehensive

hotspot

Medicare details structure of new drug price negotiation program

Chemotherapy drug shortage eases slightly but still widespread

Anesthesiologist group: stop taking Ozempic before surgery

Senate panel eyes new effort on drug shortages

ChatGPT in medicine: STAT answers readers' burning questions

Fauci’s Covid grilling leads GOP to weigh foreign research rules

How to save PrEP access — and even expand it

Colorectal cancer study finds potential in overlooked immune cell

Apple is now the first public company to be valued at $3 trillion

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

leisure time

Senate panel eyes new effort on drug shortages

GSK to buy asthma

Three issues to watch in global health in 2024

A Q&A with the global head of Boehringer Ingelheim's innovation unit

New Medicare drug pricing powers could soon be upended in court

Senate panel eyes new effort on drug shortages

hotspot

explore

focus

focus